Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?
The FDA approved Regeneron’s Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, and in a 56-week Phase 3 trial the 3 mg/kg dose cut the number of new abnormal bone lesions by 94% versus placebo.
Aug 27, 2026 ·
Yahoo Finance

















